CL2021001147A1 - Quimioterapia intraperitoneal mejorada con liposomas. - Google Patents

Quimioterapia intraperitoneal mejorada con liposomas.

Info

Publication number
CL2021001147A1
CL2021001147A1 CL2021001147A CL2021001147A CL2021001147A1 CL 2021001147 A1 CL2021001147 A1 CL 2021001147A1 CL 2021001147 A CL2021001147 A CL 2021001147A CL 2021001147 A CL2021001147 A CL 2021001147A CL 2021001147 A1 CL2021001147 A1 CL 2021001147A1
Authority
CL
Chile
Prior art keywords
liposome
enhanced
intraperitoneal chemotherapy
neoplasm
chemotherapy
Prior art date
Application number
CL2021001147A
Other languages
English (en)
Inventor
Michael G Oefelein
Natarajan Venkatesan
Nitin K Swarnakar
Teresa B Hong
Guru V Betageri
Ramachandran Thirucote
Lining Zhu Hutchinson
Original Assignee
Lipac Oncology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipac Oncology Llc filed Critical Lipac Oncology Llc
Publication of CL2021001147A1 publication Critical patent/CL2021001147A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN MÉTODO PARA TRATAR UNA NEOPLASIA QUE COMPRENDE ADMINISTRAR INTRAPERITONEALMENTE A UN SUJETO UNA FORMULACIÓN LIPOSOMAL QUE COMPRENDE UN FÁRMACO QUIMIOTERAPÉUTICO TAL COMO UN TAXANO, DURANTE UN TIEMPO SUFICIENTE Y EN UNA CANTIDAD EFICAZ PARA INHIBIR EL CRECIMIENTO DE LA NEOPLASIA.
CL2021001147A 2018-11-02 2021-04-30 Quimioterapia intraperitoneal mejorada con liposomas. CL2021001147A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862755026P 2018-11-02 2018-11-02

Publications (1)

Publication Number Publication Date
CL2021001147A1 true CL2021001147A1 (es) 2021-11-26

Family

ID=70462880

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001147A CL2021001147A1 (es) 2018-11-02 2021-04-30 Quimioterapia intraperitoneal mejorada con liposomas.

Country Status (16)

Country Link
US (1) US20220000777A1 (es)
EP (1) EP3873456A4 (es)
JP (1) JP2022506612A (es)
KR (1) KR20210113588A (es)
CN (1) CN113453667A (es)
AU (1) AU2019372441A1 (es)
BR (1) BR112021009940A8 (es)
CA (1) CA3118530A1 (es)
CL (1) CL2021001147A1 (es)
EA (1) EA202191228A1 (es)
IL (1) IL282860A (es)
MX (1) MX2021005110A (es)
PE (1) PE20211468A1 (es)
PH (1) PH12021551004A1 (es)
SG (1) SG11202104580PA (es)
WO (1) WO2020093044A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128173A (en) * 1975-10-28 1978-12-05 Harrison Lazarus Peritoneal fluid treatment apparatus, package and method
WO1994026253A1 (en) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
WO1996015774A1 (en) * 1994-11-18 1996-05-30 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
CA2524478A1 (en) * 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
MX2007004955A (es) * 2004-11-08 2007-06-14 Transave Inc Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) * 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2009059449A1 (en) * 2007-11-05 2009-05-14 Celsion Corporation Novel thermosensitive liposomes containing therapeutic agents
CA2842306A1 (en) * 2011-07-19 2013-01-24 Stc.Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
CN104582732A (zh) * 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
US10010481B2 (en) * 2014-07-02 2018-07-03 Paolo Gobbi Frattini S.R.L. Flexible package with a sealed sterile chamber for the reconsitution and administration of fluid medicinal or nutritional substances instillable into the body of a patient
EP3256110A4 (en) * 2015-02-13 2018-11-21 Op Nano Co., Ltd. Compositions and methods of tumor treatment utilizing nanoparticles
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
AU2017205337B2 (en) * 2016-01-07 2022-09-08 Tesorx Pharma, Llc Formulations for treating bladder cancer

Also Published As

Publication number Publication date
SG11202104580PA (en) 2021-05-28
KR20210113588A (ko) 2021-09-16
US20220000777A1 (en) 2022-01-06
EP3873456A4 (en) 2022-07-27
CN113453667A (zh) 2021-09-28
CA3118530A1 (en) 2020-05-07
MX2021005110A (es) 2021-08-24
EA202191228A1 (ru) 2021-09-24
AU2019372441A1 (en) 2021-06-10
EP3873456A1 (en) 2021-09-08
BR112021009940A2 (pt) 2021-08-17
WO2020093044A1 (en) 2020-05-07
JP2022506612A (ja) 2022-01-17
PE20211468A1 (es) 2021-08-05
IL282860A (en) 2021-06-30
PH12021551004A1 (en) 2021-10-04
BR112021009940A8 (pt) 2023-03-21

Similar Documents

Publication Publication Date Title
CL2019000542A1 (es) Compuestos de tetraciclina y métodos de uso de los mismos.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CO2017001994A2 (es) Compuestos activos hacia bromodominios
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
ECSP17048849A (es) Terapias de combinación para el tratamiento de cánceres
TW201613887A (en) Antiproliferative compounds and methods of use thereof
CL2016001345A1 (es) Producto farmacéutico que comprende a un inhibidor de la interacción mdm2-p53 y b citarabina y uso para el tratamiento del cáncer.
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
ECSP15030799A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CY1123469T1 (el) Σχηματα δοσολογιας του melflufen για καρκινο
MX2015014590A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
CL2018001493A1 (es) Nuevos derivados de fenilo
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
CO2021000087A2 (es) Combinación de factor vii y de un anticuerpo biespecífico dirigido contra los factores ix y x
CL2016002532A1 (es) Compuestos derivados de diheterociclo enlazado a cicloalquilo con actividad inhibidora de gls1 uso en el tratamiento de crecimiento celular anormal, tal como cáncer composición farmacéutica que los contiene
CL2018001719A1 (es) Tratamiento contra el mieloma múltiple (divisional solicitud 201600396)
AR099558A1 (es) Régimen de dosaje del compuesto fgf-18
CL2017000636A1 (es) Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
CL2021001147A1 (es) Quimioterapia intraperitoneal mejorada con liposomas.
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
JOP20190159B1 (ar) توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية